Iterum Therapeutics
Manufacturing · Ireland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
25-28 N Wall Quay, Dublin, South Dublin,...Phone Number
+353 16694820Website
www.iterumtx.comRevenue
<$5 MillionStock Symbol
ITRMIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Explore more
Iterum Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iterum Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Iterum Therapeutics recently announced quarterly report
Product Launch: Get notified when Iterum Therapeutics launches new products
Click to see if Iterum Therapeutics had a recent Job posting/layoffs
Check out if Iterum Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Iterum Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Iterum Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Iterum Therapeutics
Iterum Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Iterum Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Iterum Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Iterum Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Iterum Therapeutics.
Iterum Therapeutics financials insights
Gather financial insights about Iterum Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$40M
2017
Series B
$65M
2018
Stock Offering
$80M
2020
Debt
$51.9M
Iterum Therapeutics Tech Stack
A closer look at the technologies used by Iterum Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Partnership
Iterum Therapeutics has signed a product commercialization agreement with Eversana, a provider of global services to the life sciences industry. This partnership aims to efficiently bring Orlinda to the U.S. market, with an expected launch by the fourth quarter of this year.
Partnership, Product Launch, Pharmaceuticals
Project
Pharmaceuticals
Iterum Therapeutics News & Media
Iterum Therapeutics Provides Business Update
--Expanded Market Access and Patent Protection for ORLYNVAH™Iterum Therapeutics Provides Business Update
DUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update.Iterum Therapeutics Provides Business Update
DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update.Iterum Therapeutics Provides Business Update
DUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Iterum Therapeutics
Sign Up For FreeTo access detailed company insights
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tra... Read More
